Differences between nicotine and cocaine-induced conditioned place preferences.
In previous studies, we found differences between nicotine and cocaine-induced changes in the levels of neurotransmitters in various brain areas, which suggested differences in their reward - preference mechanisms. The present study was based on the idea that drug preference is modulated by a number of different factors, among them several neurotransmitters and their receptors, and antagonists of specific receptors will influence preference. We also assumed that the factors (components of reward mechanisms) involved are different in the case of different drugs. We compared the inhibition of nicotine preference with cocaine preference. We assayed preference as conditioned place preference (CPP) and measured CPP inhibition by receptor subtype antagonists using mice. In general, induced CPP of cocaine was stronger than of nicotine as shown by more time spent in the nonpreferred area after conditioning with cocaine. We measured inhibition by four antagonists: mecamylamine, atropine, SCH23390, and phentolamine: antagonists respectively of nicotinic, and muscarinic acetylcholine, dopamine D1, and alpha noradrenergic receptors. The inhibition by the antagonists of cocaine CPP was lower in most instances than that of nicotine CPP. Atropine and SCH23390 inhibited nicotine and cocaine CPP approximately to the same degree, while the inhibition by mecamylamine and phentolamine of nicotine CPP was 100%; that of cocaine was 20% and 0, respectively. We conclude that several receptor systems and transmitters play a role in drug preference, some represent essential elements or circuits, some may be only required partially or their role can be partially substituted. The composition of such systems is different for different drugs - in the present study, some of the components influencing CPP are different for nicotine as opposed to cocaine.
Sershen
H
H
Nathan Kline Institute, Orangeburg, NY 10962, USA. Sershen@nki.rfmh.org
Hashim
A
A
Lajtha
A
A
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology; D003042:Cocaine / Q000494:pharmacology*; D003214:Conditioning, Classical / Q000187:drug effects*; D018492:Dopamine Antagonists / Q000494:pharmacology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009538:Nicotine / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D013028:Space Perception / Q000187:drug effects*
D000317:Adrenergic alpha-Antagonists; D001552:Benzazepines; D018492:Dopamine Antagonists; D018765:Dopamine Uptake Inhibitors; D018727:Muscarinic Antagonists; D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; C534628:SCH 23390; D008464:Mecamylamine; D009538:Nicotine; D001285:Atropine; D003042:Cocaine; D010646:Phentolamine